CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy

NCT ID: NCT04913896

Last Updated: 2021-06-04

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-06-01
• Study Completion Date: 2023-06-01

Brief Summary

This is a prospective and observational clinical study for seeking out a better way to predict the pathologic complete response (pCR) in patients with advanced gastric cancer (AGC) based on the post-neoadjuvant treatment Magnetic Resonance Imaging (MRI) and CT data. This study will help the surgeons to better formulate treatment regimens for gastric cancer in the clinical practice.

Detailed Description

With the gradual development of neoadjuvant immunotherapy and/or chemotherapy in the clinic, the pCR has become more and more accessible in the AGC. Preoperative accurate prediction of pCR is of great clinical significance. The contrast-enhanced CT and 3.0T MRI were carried out in patients within 1 week prior to commencing neoadjuvant treatment, as well as 1 week within surgery after the completion of neoadjuvant treatment, respectively. Based on the information extracted from the CT/MRI, the clinical completed response (cCR) and the clinical T staging were compared with pCR, pathologic T staging. The pathologic results were considered as the golden standard. With the ROC curve analysis, the diagnosis coincidence rate, sensitivity and specificity were assessed. The AI prediction model would be constructed and trained. The depth convolution neural network based on contrast-enhanced CT and multi-modal MR quantitative images which can automatically mine key images characterization, combined with imaging features and histopathologic response, could further help to improve the prediction of response of gastric cancer treated with systematic therapy. The abdominal contrast-enhanced CT will focus on parameters: Local T Staging, nodal status, diameter, according to RECIST 1.1. MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will focus on parameters: DWI & ADC value (preferably on a single camera with reproducible ADC value), Local T Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.

Conditions

Gastric Cancer; Magnetic Resonance Imaging; Tomography, X-Ray Computed; Neoadjuvant Immunotherapy; Neoadjuvant Chemotherapy

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Single Group Assignment

Patients with AGC who underwent neoadjuvant immunotherapy and/or chemotherapy would recieve MRI and CT examination before and after 3 cycles treatment.

PD-1 inhibitor

Intervention Type: DRUG

SOX regimen for 3 cycles and/or PD-1 inhibitor before surgery

Interventions

PD-1 inhibitor

SOX regimen for 3 cycles and/or PD-1 inhibitor before surgery

Intervention Type: DRUG

Other Intervention Names

Oxaliplatin; Tiggio

Eligibility Criteria

Inclusion Criteria

1. Age 18 Years to 80 Years

2. Consecutive patients with preoperative pathologically confirmed AGC by endoscopy and preoperative imaging data (CT/MRI) were included.

3. Clinical staging Ⅱ-Ⅲ according to the UICC/AJCC 8th guideline for gastric cancer without distant metastasis.

4. Suitable for pre-operative chemotherapy, immunotherapy and surgical resection

5. No contraindications for CT/MRI examination.

6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

7. The patients participate in this study with informed consent.

Exclusion Criteria

1. Patients with a history of previous chemotherapy or immunotherapy.

2. The patients couldn't perform MSCT or MR scanning or artefacts affect the evaluation.

3. The patients are extremely anxious and uncooperative about surgery or neoadjuvant therapy.

4. The patients refuse to participate in the project.

5. Pregnancy, lactation or inadequate contraception

6. Pacemaker or implanted defibrillator

7. Patients with a history of psychological illness or condition such as to interfere with the patient's ability to understand requirements of the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The First Hospital of Jilin University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

quan wang, MD

Role: PRINCIPAL_INVESTIGATOR

The First Hospital of Jilin University

Central Contacts

quan wang, MD

Role: CONTACT

wquan@jlu.edu.cn

15843073207

Other Identifiers

STARS-GC03

Identifier Type: -

Identifier Source: org_study_id